AstraZeneca announces ADAURA trial meets secondary endpoint

Results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso demonstrated a statistically significant and clinically meaningful improvement in overall survival, or OS, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent. In May 2020, AstraZeneca announced Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival, or DFS, in this setting. In September 2022, updated results demonstrated a median DFS of nearly five and a half years. Per the ADAURA trial protocol, patients on placebo that recurred with metastatic disease had the opportunity to receive open-label Tagrisso. The safety and tolerability of Tagrisso in the ADAURA trial were consistent with its established profile and no new safety concerns were reported.